|
|
|
201-500 employees
View all
|
|
biotechnology
|
|
395 Winchester Ave.,New Haven,Connecticut,US
|
|
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
|
Arvinas Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
75%
|
The widely used Arvinas email format is {first}.{last} (e.g. [email protected]) with 75% adoption across the company.
To contact Arvinas customer service number in your country click here to find.
Diana Alicea is the CEO of Arvinas. Or you may call 7183146190
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.